Skip to main content

Moderna, Inc. statistics

  • MRNA · Nasdaq
  • Biotechnology
  • S&P 500
$223.37−3.45%Close 13 Nov 2026 · Market value $87.52B

Valuation and share-price figures are struck on the latest close (13 Nov 2026); the others are read from the company's reports. A figure that cannot be worked out, such as a P/E after a loss, is left out.

Valuation

Moderna, Inc. is valued at $87.52B on its latest close.

Market value$87.52B
Enterprise value$88.68B
Price / sales34.66
Price / book12.80
EV / sales35.12
Free cash flow yield−2.3%

Share price

Latest close$223.37
Day's change−3.4%
52-week high$280.80
52-week low$22.28
From 52-week high−20.5%
Return · 1 month+2.5%
Return · 3 months+67.5%
Return · year to date+657%
Return · 1 year+736%
Beta · 1 year against the S&P 5002.37
50-day average$201.67
200-day average$96.41
RSI 1449.7
Average volume · 20 sessions14.9M

Margins and returns

For fiscal 2025, as filed.

Gross margin55.3%
Operating margin−158%
Net margin−145%
Free cash flow margin−106%
Return on equity−28.9%
Return on assets−18.3%
Return on invested capital−40.8%
Return on invested capital, 5-year average26.4%
Return on capital employed−27.6%
Stock-based compensation / revenue24.8%

Financial position

At the end of fiscal 2025.

Cash and equivalents$2.60B
Total debt$670.0M
Net debt−$5.13B
Current ratio3.29
Quick ratio3.22
Debt / equity0.08

Growth

Revenue, latest quarter on a year+29.2%
Revenue, twelve months on a year+13.1%
Revenue, 5-year compound+19.3%

Shares and dividends

For fiscal 2025, as filed.

Diluted shares389M
Shares outstanding, 5-year compound+0.4%
Net share repurchases−$15.00M

Taxes

For fiscal 2025, as filed.

Income tax expense$54.00M
Effective tax rate−2.0%

MRNA in the terminal

Valuation against the company's own history, a cash-flow valuation, peers, charts and alerts.